keyword
MENU ▼
Read by QxMD icon Read
search

Endometrioid

keyword
https://www.readbyqxmd.com/read/28816970/skin-metastases-in-epithelial-ovarian-and-fallopian-tube-carcinoma
#1
Isao Otsuka, Takuto Matsuura
This study aimed to investigate the clinical features and outcomes of skin metastasis in ovarian and fallopian tube carcinomas.We studied patients with epithelial ovarian or fallopian tube carcinoma who developed skin metastasis from 2001 through 2012, and were also treated with chemotherapy and/or surgery.Skin metastases were classified as umbilical metastasis (Sister Joseph nodule [SJN]) and nonumbilical metastasis. Patients who developed skin metastases at paracentesis sites were excluded.Of the 206 patients treated, 12 (5...
August 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28815572/risk-of-second-primary-cancers-in-women-diagnosed-with-endometrial-cancer-in-german-and-swedish-cancer-registries
#2
Tianhui Chen, Hermann Brenner, Mahdi Fallah, Lina Jansen, Felipe A Castro, Karla Geiss, Bernd Holleczek, Alexander Katalinic, Sabine Luttmann, Kristina Sundquist, Meike Ressing, Leiting Xu, Kari Hemminki
Along with the increasing incidence and favorable prognosis, more women diagnosed with endometrial cancer may develop second primary cancers (SPCs). We aimed at investigating risk of SPCs after endometrial cancer in Germany and Sweden to provide insight into prevention strategies for SPCs. Endometrial cancer patients diagnosed at age ≥15 years in Germany during 1997-2011 and in Sweden nationwide during 1997-2012 were selected. Standardized incidence ratios (SIRs), calculated as the ratio of observed to expected numbers of cases, were used to assess the risk of a specific second cancer after endometrial cancer for both German and Swedish datasets...
August 17, 2017: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/28810294/-morphologic-features-of-fallopian-tubal-epithelium-in-pelvic-high-grade-serous-carcinoma
#3
R J Zhao, Y Y Wang, Z Li, K Y Wu, L F Kong, W X Zheng
Objective: To study the pathologic features of fallopian tubal epithelium in patients with pelvic high-grade serous carcinoma (HGSC), to investigate its role in pelvic serous carcinogenesis and to reclassify the primary site of HGSC based on recently proposed criteria. Methods: The fallopian tubes in 58 cases of pelvic HGSC (54 cases of ovarian primary, 3 cases of tubal primary, 1 case of peritoneum) and 25 cases of pelvic non-HGSC (5 cases of ovarian low-grade serous cancer, 9 cases of endometrioid cancer, and 11 cases of clear cell ovary carcinoma) were collected from June 2015 to December 2016, and serially examined under light microscope (SEE-FIM protocol)...
August 8, 2017: Zhonghua Bing Li Xue za Zhi Chinese Journal of Pathology
https://www.readbyqxmd.com/read/28802955/hysterscopic-resection-of-premalignant-and-malignant-endometrial-polyps-is-it-a-safe-alternative-to-hysterectomy
#4
Osnat Elyashiv, Ron Sagiv, Ram Kerner, Ran Keidar, Joseph Menczer, Tally Levy
STUDY OBJECTIVE: The standard treatment of endometrial cancer (EC) and complex atypical hyperplasia (CAH) is hysterectomy with or without adnexectomy. In the last decade, several centers have attempted to perform hysteroscopic resection of malignant and pre-malignant polyps as an alternative to hysterectomy. In the present study, we evaluated the safety of this procedure in regard to residual uterine pathology. DESIGN: Retrospective chart review DESIGN CLASSIFICATION: Canadian Task Force classification II-2 SETTING: University hospital PATIENTS: 1766 women who underwent hysteroscopic polypectomy during the years 1998-2016 MEASUREMENTS: Patients with CAH and endometrioid type EC in the removed polyps who underwent hysterectomy were included in the study...
August 9, 2017: Journal of Minimally Invasive Gynecology
https://www.readbyqxmd.com/read/28802188/risk-of-uterine-cancer-for-brca1-and-brca2-mutation-carriers
#5
Y C Lee, R L Milne, S Lheureux, M Friedlander, S A McLachlan, K L Martin, M Q Bernardini, C Smith, S Picken, S Nesci, J L Hopper, K A Phillips
BACKGROUND: Whether BRCA1 and BRCA2 mutation carriers have a clinically relevant elevated risk of uterine cancer has implications for risk-reducing surgery. AIM: This multicentre, prospective cohort study assessed uterine cancer risk for mutation carriers compared with the general population. METHODS: Eligible mutation carriers were enrolled in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab) cohort study, had a uterus present and no history of uterine cancer at cohort entry...
August 9, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28800945/impact-of-age-at-diagnosis-on-racial-disparities-in-endometrial-cancer-patients
#6
Christopher M Tarney, Chunqiao Tian, Guisong Wang, Elizabeth A Dubil, Nicholas W Bateman, John K Chan, Mohamed A Elshaikh, Michele L Cote, Joellen M Schildkraut, Craig D Shriver, Thomas P Conrads, Chad A Hamilton, G Larry Maxwell, Kathleen M Darcy
INTRODUCTION: Although black patients with endometrial cancer (EC) have worse survival compared with white patients, the interaction between age/race has not been examined. The primary objective was to evaluate the impact of age at diagnosis on racial disparities in disease presentation and outcome in EC. METHODS: We evaluated women diagnosed with EC between 1991 and 2010 from the Surveillance, Epidemiology, and End Results. Mutation status for TP53 or PTEN, or with the aggressive integrative, transcript-based, or somatic copy number alteration-based molecular subtype were acquired from the Cancer Genome Atlas...
August 8, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28795426/blinded-histopathological-characterisation-of-pole-exonuclease-domain-mutant-endometrial-cancers-sheep-in-wolf-s-clothing
#7
Inge C Van Gool, Jef E H Ubachs, Ellen Stelloo, Cor D de Kroon, Jelle J Goeman, Vincent T H B M Smit, Carien L Creutzberg, Tjalling Bosse
AIMS: POLE exonuclease domain mutations identify a subset of endometrial cancer (EC) patients with an excellent prognosis. Implementation of this biomarker has been suggested to refine adjuvant treatment decisions, but the necessary sequencing is not widely performed and relatively expensive. Therefore, we aimed to identify histopathological and immunohistochemical characteristics to aid the detection of POLE-mutant ECs. METHODS AND RESULTS: Fifty-one POLE-mutant endometrioid, 67 POLE-wild-type endometrioid and 15 POLE-wild-type serous ECs were included (total N=133)...
August 10, 2017: Histopathology
https://www.readbyqxmd.com/read/28794448/prognostic-impact-of-cd133-expression-in-endometrial-cancer-patients
#8
G Mancebo, J M Sole-Sedeno, O Pino, E Miralpeix, S Mojal, L Garrigos, B Lloveras, P Navarro, J Gibert, M Lorenzo, I Aran, R Carreras, F Alameda
To assess the impact of CD133 expression on the prognosis of endometrioid endometrial carcinoma (EEC). We retrospectively assessed CD133 expression in tissue microarray of 116 surgically treated FIGO I-III EEC. Tumors with ≥10% of CD133-expressing cells were considered CD133-positive (CD133+). On the basis of CD133 expression, clinical and pathological parameters, progression-free survival (PFS) and overall survival (OS) were evaluated. Of the EEC studied 85.2% showed CD133-expressing cells. Only 61% (n = 66) of EEC presented ≥10% of CD133 expressing cells and were considered CD133+...
August 9, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28791695/use-of-antidepressants-and-risk-of-epithelial-ovarian-cancer
#9
Lina S Mørch, Christian Dehlendorff, Louise Baandrup, Søren Friis, Susanne K Kjaer
Antidepressants are widely prescribed among women to treat depression and anxiety disorders, but studies of their effects on gynecological cancer risk are sparse. We assessed associations between various antidepressants and risk of epithelial ovarian cancer. By using Danish nationwide registers, we identified all women (cases) aged 30 to 84 years with incident epithelial (serous, endometrioid, clear cell or mucinous) ovarian cancer during 2000-2011 (n= 4,103) and matched each case to 20 population controls (n=58,706) by risk-set matching...
August 9, 2017: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/28790116/targeted-proteomics-identifies-proteomic-signatures-in-liquid-biopsies-of-the-endometrium-to-diagnose-endometrial-cancer-and-assist-in-the-prediction-of-the-optimal-surgical-treatment
#10
Elena Martinez, Antoine Lesur, Laura Devis, Silvia Cabrera, Xavier Matias-Guiu, Marc Hirschfeld, Jasmin Asberger, Jan van Oostrum, María de Los Ángeles Casares de Cal, Antonio Gómez-Tato, Jaume Reventos, Bruno Domon, Eva Colas, Antonio Gil-Moreno
PURPOSE: Endometrial cancer (EC) diagnosis relies on the observation of tumor cells in endometrial biopsies obtained by aspiration i.e., uterine aspirates), but it is associated with 22% undiagnosed patients and up to 50% of incorrectly assigned EC histotype and grade. We aimed to identify biomarker signatures in the fluid fraction of these biopsies to overcome these limitations. EXPERIMENTAL DESIGN: The levels of 52 proteins were measured in the fluid fraction of uterine aspirates from 116 patients by LC-PRM, the latest generation of targeted mass-spectrometry acquisition...
August 8, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28779965/assessing-the-risk-of-pelvic-and-para-aortic-nodal-involvement-in-apparent-early-stage-ovarian-cancer-a-predictors-and-nomogram-based-analyses
#11
Giorgio Bogani, Elena Tagliabue, Antonino Ditto, Mauro Signorelli, Fabio Martinelli, Jvan Casarin, Valentina Chiappa, Giulia Dondi, Umberto Leone Roberti Maggiore, Cono Scaffa, Chiara Borghi, Luca Montanelli, Domenica Lorusso, Francesco Raspagliesi
OBJECTIVE: To estimate the prevalence of lymph node involvement in early-stage epithelial ovarian cancer in order to assess the prognostic value of lymph node dissection. METHODS: Data of consecutive patients undergoing staging for early-stage epithelial ovarian cancer were retrospectively evaluated. Logistic regression and a nomogram-based analysis were used to assess the risk of lymph node involvement. RESULTS: Overall, 290 patients were included...
August 2, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28777147/ttf-1-positive-metastatic-endometrioid-carcinoma-a-case-report-and-review-of-literature-of-a-potential-diagnostic-pitfall
#12
François Casteillo, Pierre Fournel, Vanessa Da Cruz, Georgia Karpathiou, Claire Boutet, Jean-Philippe Jacquin, Claire Tissot, Vincent Meyer-Bisch, Michel Péoc'h, Fabien Forest
A 75-year-old female patient, nonsmoker was addressed to our institution for a fracture of C5 vertebra with spinal cord compression by a tumor mass invading surrounding soft tissue. She had a previous history of breast ductal carcinoma and endometrioid carcinoma. Biopsy of the tumor mass showed a TTF-1-positive carcinoma. Molecular study showed a E545K mutation of PIK3CA. Lung imaging showed multiple nodules evocative of metastasis rather than a primitive tumor. Reviewing of slides of endometrioid carcinoma showed areas positive for TTF1, and the same E545K mutation was found in endometrial tumor...
August 2, 2017: Applied Immunohistochemistry & Molecular Morphology: AIMM
https://www.readbyqxmd.com/read/28776572/molecular-based-classification-algorithm-for-endometrial-carcinoma-categorizes-ovarian-endometrioid-carcinoma-into-prognostically-significant-groups
#13
Carlos Parra-Herran, Jordan Lerner-Ellis, Bin Xu, Sam Khalouei, Dina Bassiouny, Matthew Cesari, Nadia Ismiil, Sharon Nofech-Mozes
The Cancer Genome Atlas classification divides endometrial carcinoma in biologically distinct groups, and testing for p53, mismatch repair proteins (MMR), and polymerase ɛ (POLE) exonuclease domain mutations has been shown to predict the molecular subgroup and clinical outcome. While abnormalities in these markers have been described in ovarian endometrioid carcinoma, their role in predicting its molecular profile and prognosis is still not fully explored. Patients with ovarian endometrioid carcinomas treated surgically in a 14-year period were selected...
August 4, 2017: Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc
https://www.readbyqxmd.com/read/28764184/ichthyosis-uteri-associated-with-endometrial-adenocarcinoma-a-case-report
#14
Nishu Bhardwaj, Preeti Diwaker, Priyanka Gogoi, Neelam Wadhwa, Kiran Mishra
The replacement of the entire or extensive parts of endometrial lining by stratified squamous epithelium is a rare entity known as ichthyosis uteri. It is considered to be a benign condition but may be associated with dysplastic changes and primary squamous cell carcinoma of the endometrium. Its association with endometrial adenocarcinoma is very rare. The aetiology of this condition is not clearly understood till date. We report a case of ichthyosis uteri associated with endometrial adenocarcinoma in a 70-year-old female who presented with complaint of per-vaginal bleeding for six months and underwent hysterectomy after being diagnosed with endometrial carcinoma...
June 2017: Journal of Clinical and Diagnostic Research: JCDR
https://www.readbyqxmd.com/read/28764180/high-grade-serous-cystadenocarcinoma-of-testis-case-report-of-a-rare-ovarian-epithelial-type-tumour
#15
Sithara Aravind, Sangeetha K Nayanar, R Varadharajaperumal, T V Satheeshbabu, Satheesan Balasubramanian
Ovarian epithelial type tumour of testis are extremely rare tumours that resemble ovarian surface epithelial tumours. They usually present as testicular or paratesticular tumours and can be serous, mucinous, endometrioid or Brenner tumour. Serous and mucinous types account for the majority of tumours. The tumours are benign, borderline or malignant, commonly borderline. Here, we report a case of high grade serous cyst adenocarcinoma of testis which manifested as extensive metastasis in supraclavicular, mediastinal and abdominopelvic groups of lymph nodes, lung and adrenal gland without clinical evidence of an overt primary tumour...
June 2017: Journal of Clinical and Diagnostic Research: JCDR
https://www.readbyqxmd.com/read/28763364/adjuvant-therapy-use-and-survival-in-stage-ii-endometrial-cancer
#16
Nataniel H Lester-Coll, Melissa R Young, Henry S Park, Elena S Ratner, Babak Litkouhi, Shari Damast
OBJECTIVE: Radiotherapy (RT) is an established adjuvant treatment for stage II endometrioid endometrial carcinoma (EEC). The role of chemotherapy (CT) in stage II EEC is less proven. We used the National Cancer Data Base to identify factors associated with adjuvant CT in stage II EEC and to explore whether receipt of CT was associated with improved overall survival (OS). METHODS/MATERIALS: Women diagnosed in 2010 to 2013 with International Federation of Obstetrics and Gynecology stage II EEC (grades 1-3) after hysterectomy and bilateral salpingo-oophorectomy were identified in the National Cancer Data Base...
August 1, 2017: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/28762064/nomogram-with-potential-clinical-use-to-predict-lymph-node-metastasis-in-endometrial-cancer-patients-diagnosed-incidentally-by-postoperative-pathological-assessment
#17
Salih Taşkın, Yavuz Emre Şükür, Bulut Varlı, Kazibe Koyuncu, Mehmet Murat Seval, Can Ateş, Selcen Yüksel, Mete Güngör, Fırat Ortaç
PURPOSE: To determine the clinical and pathological risk factors for lymph node metastasis (LNM) in patients with endometrial cancer and to create a nomogram to predict LNM in patients without surgical staging. METHODS: All patients with endometrial adenocarcinoma who were treated surgically at a university based gynecologic oncology clinic between January 2011 and December 2014 were recruited. Women with endometrial adenocarcinoma who were surgically staged including lymphadenectomy were included in the study...
July 31, 2017: Archives of Gynecology and Obstetrics
https://www.readbyqxmd.com/read/28759630/c77g-in-ptprc-cd45-is-no-risk-allele-for-ovarian-cancer-but-associated-with-less-aggressive-disease
#18
Johannes Landskron, Sigrid M Kraggerud, Elisabeth Wik, Anne Dørum, Merete Bjørnslett, Espen Melum, Øystein Helland, Line Bjørge, Ragnhild A Lothe, Helga B Salvesen, Kjetil Taskén
The pan lymphocyte marker CD45 exists in various isoforms arising from alternative splicing of the exons 4, 5 and 6. While naïve T cells express CD45RA translated from an mRNA containing exon 4, exons 4-6 are spliced out to encode the shorter CD45R0 in antigen-experienced effector/memory T cells. The SNP C77G (rs17612648) is located in exon 4 and blocks the exon's differential splicing from the pre-mRNA, enforcing expression of CD45RA. Several studies have linked C77G to autoimmune diseases but lack of validation in other cohorts has left its role elusive...
2017: PloS One
https://www.readbyqxmd.com/read/28759021/asct2-regulates-glutamine-uptake-and-cell-growth-in-endometrial-carcinoma
#19
A D Marshall, M van Geldermalsen, N J Otte, T Lum, M Vellozzi, A Thoeng, A Pang, R Nagarajah, B Zhang, Q Wang, L Anderson, J E J Rasko, J Holst
Glutamine commonly becomes a conditionally essential amino acid in cancer. Glutamine is supplied to the cell by transporters such as ASCT2 (SLC1A5), which is frequently upregulated in multiple cancers. Here we investigated the expression of ASCT2 in endometrial carcinoma, and evaluated the contribution of ASCT2 to glutamine uptake and endometrial cancer cell growth. Analysis of human gene expression data showed that ASCT2 was significantly upregulated in both endometrioid and serous subtypes of endometrial carcinoma, compared to normal, age-matched endometrium...
July 31, 2017: Oncogenesis
https://www.readbyqxmd.com/read/28754483/olaparib-tablets-as-maintenance-therapy-in-patients-with-platinum-sensitive-relapsed-ovarian-cancer-and-a-brca1-2-mutation-solo2-engot-ov21-a-double-blind-randomised-placebo-controlled-phase-3-trial
#20
Eric Pujade-Lauraine, Jonathan A Ledermann, Frédéric Selle, Val Gebski, Richard T Penson, Amit M Oza, Jacob Korach, Tomasz Huzarski, Andrés Poveda, Sandro Pignata, Michael Friedlander, Nicoletta Colombo, Philipp Harter, Keiichi Fujiwara, Isabelle Ray-Coquard, Susana Banerjee, Joyce Liu, Elizabeth S Lowe, Ralph Bloomfield, Patricia Pautier
BACKGROUND: Olaparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, has previously shown efficacy in a phase 2 study when given in capsule formulation to all-comer patients with platinum-sensitive, relapsed high-grade serous ovarian cancer. We aimed to confirm these findings in patients with a BRCA1 or BRCA2 (BRCA1/2) mutation using a tablet formulation of olaparib. METHODS: This international, multicentre, double-blind, randomised, placebo-controlled, phase 3 trial evaluated olaparib tablet maintenance treatment in platinum-sensitive, relapsed ovarian cancer patients with a BRCA1/2 mutation who had received at least two lines of previous chemotherapy...
July 25, 2017: Lancet Oncology
keyword
keyword
80266
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"